Liquid Biopsy Expansion

The appointment coincides with the firm’s ongoing development of its telomere‑analysis platform, which underpins Telo Genomics’ diagnostic and prognostic tests. The company maintains a portfolio of over 160 peer‑reviewed publications and more than 30 clinical studies involving in excess of 3,000 patients. Its flagship product, Telo‑MM, is advancing through clinical development for Multiple Myeloma, promising actionable information to treating physicians. Telo Genomics remains focused on expanding liquid‑biopsy solutions across oncology and neurological disease spaces, leveraging its proprietary technology to improve patient care.